您的位置: 首页 » 法律资料网 » 法律论文 »

行政判决及其法律适用问题初探/曹伟

作者:法律资料网 时间:2024-06-17 04:07:57  浏览:9733   来源:法律资料网
下载地址: 点击此处下载
  【内容摘要】:行政判决是人民法院在审理行政案件时,根据认定的事实和适用相关法律法规,以国家审判机关的名义依法对案件实体问题所作的决判,是人民法院对行政机关进行司法监督最有效的方法,对于监督和维护行政机关依法行政,保护公民,法人或者其他组织的合法权益具有重要的社会意义,是国家意志的体现,行政判决一旦生效就对当事人以及人民法院自身产生拘束力。对于行政诉讼案件,根据《行政诉讼法》及最高人民法院《关于执行〈行政诉讼法〉若干问题的解释》?以下简称《解释》〕的规定,人民法院可以根据不同情况分别做出维持判决、撤销判决、履行判决、变更判决、确认判决、驳回诉讼请求判决、行政赔偿判决七类判决结论,本文试就七类判决在法律通用的问题略陈已见,以期方家指正。


一、维持判决

维持判决是人民法院经审查,认定具体行政行为合法有效,对其予以维持,确认其效力的判决。该判决是人民法院对具体行政行为合法性的肯定,是对行政法律关系的维护。按照《行政诉讼法》第54条第(1)项的规定,人民法院在做出维持判决时应同时满足三个条件:

1、证据确凿。指做出行政行为所依据的证据材料真实、可靠,行政行为是否具有充分证据属事实审查,即对具体行政行为所根据的事实进行审查。没有足够确凿的证据证明事实成立,人民法院不能做出维持原判。

2、适用法律、法规正确。指具体行政行为所使用的法律、法规及相应条款正确合理。

3、符合规定的行政程序,行政机关做出具体行政行为为必须符合法律法规规定的行政程序以及行政程序的一般原则。

人民法院在做出维持判决时,应遵循以下规则对被诉行为予以审查,以确定应适用的法律规范。首先,要遵循行政审判适用法律的一般原则,对被诉行为所依据的事实进行审查,为正确适用法律提供事实基础。其次,要对被诉具体行政行为所适用的法律、法规及其相关相应条款是否正确合理进行审查,以确定被诉行政行为是否适用维持判决。具体审查内容包括:(1)适用的法律法规是否现行有效,尚未生效或已废止的法律不得适用彼法,应适用此条款而适用彼条款的情形;(3)排除适用了不应当适用和应当适用而没有适用的情形;(4)审查适用法律法规的主体是否合法,其是否在法定职权范围内行使职权。再者,应当注意用行政程序规范以及行政程序一般原则对被诉行政行为的程序合法性进行审查,以确认其是否符合法定程序,能否判决予以维持。

二、撤销判决

撤销判决,是指人民法院经过审查,认定被诉行政行为违法,对其予以撤销,否定其效力的判决。行政诉讼的主要目的就是为了撤销违法的,对公民合法权益产生侵害的行政行为。通过人民法院的撤销判决,可以对违法的具体行政行为予以纠正,从而确保行政法律秩序的正常运行,依法行政的真正实现。撤销判决有全部撤销判决、部分撤销判决和撤销并重新作出具体行政行为判决三种具体形式。根据《行政诉讼法》第54条第2项的规定,做出撤销判决,应当具有下列情形之一:

1、主要证据不足。指行政机关实施的具体行政行为缺乏必要的证据,不足以证明该具体行政行为所认定的事实情况,行政行为主要证据不足,人民法院应予以判决撤销。

2、适用法律、法规错误。指行政机关在实施行政行为时错误地援用了法律法规。主要有以下表现:①选择适用的法律、法规不正确;②选择适用的法律法规条款不正确;③适用无效的法律法规;④适用法律法规不全面;⑤违反法律冲突适用规则;⑥行政行为没有法律法规为依据。

3、违反法律规定的行政程序。指行政机关实施行政行为时违反行政程序法规规范。行政行为违反法定行政程序,指导致被撤销的法律后果。违反法定程序的表现形式主要有:①步骤或顺序违法;②行政活动的形式违法;③时限违法。

4、超越职权

超越职权是指行政机关实施具体行政行为时超越了法律法规授予的权力界限。人民法院对被诉具体行政行为是否超越职权,可以从以下几个方面予以审查:①被诉行政行为是否行使了宪法,法律没有词语的权力,即无权限。②被诉行政行为是否行使了法律词语其他行政机关的权力,即事物越权。包括行政机关行使国家权力机关,司法机关的职权,以及某一行政机关行使了其他行政机关职权的情形。③被诉行政行为是否超(行政处罚的行政机关在法定处罚种类和幅度以外事实处罚:二是地域越权,即行政机关行使职权超越了地域管辖范围:三是层级越权,包括下级行政机关行使了上级行政机关的权限和上级行政机关行使了下级行政机关的权限。

5、滥用职权

滥用职权,是指行政机关的具体行政行为违反法律授予该职权的目的?做出行政行为时存在主观恶意?。人民法院可以从以下几个方面审查被诉行为是否构成滥用职权:①被诉行政行为的做出是否违背法律的目的。行政机关关在行使法律赐予的权力时,不得与法律追求的目的相背离,否则就是滥用职权。如被告的罚款决定不是为了制裁违反行政法义务的行为,而是出于为了收集资金的目的,就构成滥用职权。②被诉行政行为的做出是否掺杂了不适当的考虑。包括行政机关在做出被诉行政行为时是否考虑的重要因素。如被告在做出被诉行政行为时不适当地考虑了相对人的身份及相对人与行政机关共工作人员的亲属关系等,该行政决定即属滥用职权。③被诉行政行为是否有违反比列原则的情形,包括被告在行使职权做出具体行政行为时是否有独断专横,反复无常以及同等情况下不同等对待等现象。如对同以法律法规的有关条款在同类案件中先后做出不同的解释,造成同类案件不同处理以及对违法轻者重罚,重者轻罚等现象。

三、履行判决

履行判决是针对被告不作为行为而采用的判决形式,是指人民法院经审查,认定被告负有法定职责而未履行且无正当理由所做出的责令被告限期履行职责的判决。

《行政诉讼法》第54条第三项规定:“被告不履或者拖延履行法定职责的,判决其在一定期限内履行。”据此,人民法院在做出履行判决时应同时慢足以下条件:①被告依法负有法定职责;②被告对相对人的申请不予答复,即存在不履行或拖延履行法定职责的情形;③被告不履行或拖延履行法定职责无正当理由。

根据履行判决的适用条件,人民法院在审理被告不作为案件时,应从以下几个方面对被诉讼行为进行审查,以最终确定其应适用的法律规范。

1、被告是否负有与原告申请事项相关的法定职责。被告负有相关的法定职责才有可能适用履行判决的相关法律条款。否则,应适用驳回诉讼请求的判决类型与法律条款驳回原告的诉讼请求。

2、被告是否有对相对人的申请不予答复即不履行或拖延履行法定职责的情形。具体审查以下内容:①相对人是否提出相关的申请,对此应有相对人负举证责任,相对人不能举证的,则其诉讼被告不作为的理由不能成立,应适用驳回诉讼请求的判决类型及相关条款。②被告对相对人的申请是否做出明确的意思表示。若做出明确的意思表示,无论该意思表示是同意或批准,还是拒绝或不批准,则都构不成不作为,不适用履行判决的类型及条款。同意或批准的意思表示意味着已作为且已答复了相对人的申请,只不过是未具体执行;拒绝或不批准的明示拒绝行为,实际上是被告履行职责的否定性表现形式,是一种作为的形式,对此应适用撤销、确定等判决类型及法律条款。③被告不予答复的期限是否超过法定的合理的期限。

《解释》第39条规定:“共民、法人或其他组织申请行政机关履行法定职责,行政机关在接到申请之日起60日内不履行的,公民、法人或其他组织向人民法院提起诉讼,人民法院应当依法受理。法律、法规、规章和其规范性文件对行政机关履行职责的期限另有的,从其规定。“公民、法人或其他组织在紧急情况下请求行政机关履行保持其人身权、财产权的法定职责,行政机关不履行的,起诉期间不受前款规定的限制。”可见行政机关对相对人有关申请答复的合理期限通常是60日。人民法院应据此对被诉行政行为予以审查。

3、被告不履行或拖延履行法定职责无正当理由。若被告有正当理由,如无管辖权或因不可抗力等原因而导致不履行或拖延履行法定职责的,则不构成违法,也不应该做出履行判决,而应判决驳回原告的诉讼请求。

四、变更判决
下载地址: 点击此处下载

关于印发《最高人民检察院关于保护公民举报权利的规定》的通知

最高人民检察院


关于印发《最高人民检察院关于保护公民举报权利的规定》的通知
1991年5月13日,最高检

各省、自治区、直辖市人民检察院,军事检察院:
现将《最高人民检察院关于保护公民举报权利的规定》印发给你们,请认真组织检察干部学习、宣传,切实贯彻执行。各地要把贯彻执行情况、社会各方面的反映和产生的效应及时报送高检院。附:《最高人民检察院关于保护公民举报权利的规定》

附:最高人民检察院关于保护公民举报权利的规定(一九九一年五月六日第七届最高人民检察院检察委员会第六十五次会议通过)

第一条 为保障公民依法行使控告、检举的权利,维护举报人的合法权益,促进廉政建设,根据《中华人民共和国宪法》第四十一条和《中华人民共和国刑法》第一百三十一条、第一百四十六条的规定,制定本规定。
第二条 公民依法向各级检察机关举报机关、团体、企业、事业单位和国家工作人员违法犯罪行为,其人身权利、民主权利和其他合法权益应受到法律的保护。
第三条 检察机关受理公民举报和查处举报案件,必须严格保密。
1、受理举报应在固定场所进行,专人接谈,无关人员不得接待、旁听和询问。
2、举报信件的收发、拆阅、登记、转办、保管和当面或电话举报的接待、接听、记录、录音等工作,应建立健全责任制,严防泄露或遗失举报材料。
3、对举报人的姓名、工作单位、家庭住址等有关情况及举报的内容必须严格保密,举报材料不准私自摘抄和复制。
4、严禁将举报材料和举报人的有关情况透露或转给被举报单位、被举报人。向被举报单位或被举报人调查情况时,不得出示举报材料原件或复印件。
5、任何单位和个人不得追查举报人,对匿名举报除侦查工作需要外,不准鉴定笔迹。
6、向举报人核查情况时,应在做好保密工作、不暴露举报人身份的情况下进行。
7、在宣传报道和对举报有功人员的奖励工作中,除征得举报人的同意外,不得公开举报人的姓名、单位。
第四条 对违反上述第三条保密规定的责任人员,要根据情节和后果给予严肃处理,构成犯罪的,依法追究刑事责任。
第五条 任何单位和个人不得以任何借口对公民的举报,进行阻拦、压制、刁难或打击报复。
第六条 以各种借口和手段侵害举报人及其亲属、假想举报人的合法权益的,按打击报复论处。
第七条 对打击报复举报人的案件应认真受理,经调查确属打击报复的,视情节轻重,区别性质,分别做出处理:
1、国家工作人员滥用职权、假公济私,对举报人实行报复陷害构成犯罪的,应依法立案侦查,追究责任人的刑事责任。
2、以各种形式打击报复举报人不构成犯罪的,应向其所在单位的上一级主管部门提出检察建议,严肃处理。
第八条 确因受打击报复而造成人身伤害及名誉、财产、经济损失的,举报人可依法要求赔偿,或向人民法院起诉,请求损害赔偿。
第九条 公民应据实举报。凡捏造事实、制造伪证,利用举报诬告陷害他人构成犯罪的,依法追究刑事责任。
由于对事实了解不全面而发生误告、错告等检举失实的,不适用前款规定。
第十条 港澳同胞、台湾同胞、华侨和外国人因举报国家机关和国家工作人员违法犯罪行为而被打击报复的,适用本规定。
第十一条 各省、自治区、直辖市人民检察院可以根据实际情况制定实施本规定的细则。
第十二条 本规定自公布之日起施行。


Provisions for Drug Advertisement Examination

State Food and Drug Administration,State Administration for Industry and Commerceof the People’s Republic of China


Provisions for Drug Advertisement Examination



(SFDA Decree No. 27)

The Provisions for Drug Advertisement Examination, adopted by the State Food and Drug Administration and the State Administration for Industry and Commerce of the People’s Republic of China, is now issued in the decree sequence number of the State Food and Drug Administration. The Provisions shall go into effect as of the date of May 1, 2007.



Shao Mingli
Commissioner
State Food and Drug Administration

Zhou Bohua
Minister
State Administration for Industry and Commerceof the People’s Republic of China

March 13, 2007





Provisions for Drug Advertisement Examination


Article 1 The Provisions are formulated for the purposes of strengthening regulation on drug advertisements and ensuring the authenticity and legality of drug advertisements in accordance with the Advertisement Law of the People’s Republic of China (hereinafter referred to as Advertisement Law), the Drug Administration Law of the People's Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for the Implementation of Drug Administration Law of the People's Republic of China (hereinafter referred to as Regulations for the Implementation of Drug Administration Law) and other regulations related to supervision on advertisements and drugs.

Article 2 A drug advertisement refers to any advertisement published through various media or forms containing drug name, indications (functions) or other relevant contents, and shall be examined and approved in accordance with the Provisions.

Where only the names of non-prescription drugs (including adopted names and trade names) are publicized or only the names of prescription drugs (including adopted names and trade names) are publicized in professional medical or pharmaceutical journals, the examination is not required.

Article 3 The drug advertisement applied for examination shall be approved provided that it conforms to the following laws, regulations and related provisions:
(1) Advertisement Law;
(2) Drug Administration Law;
(3) Regulations for Implementation of Drug Administration Law;
(4) Criteria for Examining and Publishing Drug Advertisement;
(5) Other provisions of the State on advertisement regulation.

Article 4 The drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government are the drug advertisement examination authorities responsible for examining drug advertisements within their administrative regions. The administrative departments for industry and commerce at or above the county level are supervision and control authorities for drug advertisements.

Article 5 The State Food and Drug Administration shall guide and supervise the examination conducted by drug advertisement examination authorities and punish, in accordance with law, the examination authorities that have violated the Provisions.

Article 6 An applicant for a drug advertisement approval number must be an eligible drug manufacturer or distributor. Where the applicant is a drug distributor, the consent of the drug manufacturer is required.

An applicant may entrust an agent with the application for a drug advertisement approval number.

Article 7 An application for a drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the drug manufacturer is located.

An application for an import drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the agent of the import drug is located.

Article 8 Where a drug manufacturer or distributor applies for a drug advertisement approval number, it shall submit an Application Form for Drug Advertisement (Appendix 1) with sample manuscript (sample film or sample record) of which the content is consistent with that to be published attached, and an electronic document of drug advertisement application. It shall also submit the following proof documents that are authentic, legal and valid:
(1) Copy of the Business License of the applicant;
(2) Copy of the Drug Manufacturing Certificate or the Drug Supply Certificate of the applicant;
(3) Where the applicant is a drug distributor, the original document proving that the drug manufacturer authorizes the drug distributor to be the applicant shall be submitted;
(4) Where an agent submits an application for a drug advertisement approval number on behalf of the applicant, an original authorization letter given by the applicant to the agent, a copy of business license of the agent and other documents proving the subject’s qualifications shall be submitted;
(5) Copies of the drug approval document (including Import Drug License or Pharmaceutical Product License), copy of approved insert sheet, and label and insert sheet used in practice;
(6) For non-prescription drug advertisement, a copy of registration certificate of non-prescription drug examination or copies of relevant certificates is required;
(7) Where an applicant applies for an import drug advertisement approval number, copies of qualification certificates of the agent of the import drug shall be submitted;
(8) Where the trade name, registered trademark and patent of the drug are involved in an advertisement, copies of the valid certificates and other relevant documents proving the authenticity of the advertisement shall be submitted.

The copy of any approval document prescribed in this Article shall be sealed by the document holder.

Article 9 An advertisement application by an enterprise for a drug shall not be accepted by the drug advertisement examination authorities under any of the following circumstances:
(1) Any of the circumstances under which the application shall be rejected as prescribed in Article 20, Article 22 and Article 23 of the Provisions;
(2) An administrative procedure to withdraw a drug advertisement approval number is in process.

Article 10 After receiving an application for drug advertisement approval number, where the dossier is complete and in conformity with statutory requirements, the drug advertisement examination authority shall issue an Acceptance Notice of Drug Advertisement; where the dossier is incomplete or not conforming to the statutory requirements, one notification on all the content to be supplemented or corrected shall be given to the applicant on the spot or within five working days; if the notification to the applicant is not issued within the timeline, the application is deemed as being accepted upon the date when the dossier is received.

Article 11 Within ten working days upon accepting an application, the drug advertisement examination authority shall check the authenticity, legality and validity of the documents submitted by the applicant, and shall examine the advertisement content in accordance with law. For the drug advertisement in conformity with statutory requirements, a drug advertisement approval number shall be issued; for those not in conformity with statutory requirements, the authority shall make a decision of not issuing a drug advertisement approval number and notify the applicant of the decision with reasons in written form and the applicant’s right to apply for administrative reconsideration or to bring an administrative suit by law.

For approved drug advertisement, the drug advertisement examination authority shall report to the State Food and Drug Administration for records and send the approved Application Form for Drug Advertisement to the authority responsible for advertisement supervision and control at the same level for records. Where there is any problem in the drug advertisement reported to the State Food and Drug Administration for records, the State Food and Drug Administration shall instruct the drug advertisement examination authority to correct it.

The drug regulatory departments shall announce the approved drug advertisement timely.

Article 12 Where a drug advertisement is to be published in the province, autonomous region or municipality directly under the Central Government other than the place where the drug manufacturer and the agent of the import drug are located (hereinafter referred to as “non-local drug advertisement”), it shall, before being published, be submitted for records to the drug advertisement examination authority in the place where the advertisement is to be published.

Article 13 The following materials for non-local drug advertisement shall be submitted for record:
(1) Copy of the Application Form for Drug Advertisement;
(2) Copy of the approved drug insert sheet;
(3) For television or audio broadcast advertisement, it is required to submit the audio tape, compact disc or other medium carrier on which the content is consistent with the approved content.

The copy of any document prescribed in this Article shall be sealed by the document holder.

Article 14 For application for putting non-local drug advertisement on record in accordance with Articles 12 and Article 13 of the Provisions, the drug advertisement examination authority shall, within five working days after accepting the application, put such drug advertisement on record, endorse the word “recorded” on the Application Form for Drug Advertisement, affix the seal specific for drug advertisement examination and send the form to the supervision and control authorities for advertisements at the same level for future reference.

Where the drug advertisement examination authority of a place where a drug advertisement is to be put on record finds that the drug advertisement is not conformed with the relevant provisions, it shall fill in the Opinion on the Record of Drug Advertisement Examination (Appendix 2), submit it to the original drug advertisement examination authority for check, and copy it to the State Food and Drug Administration.

Within five working days upon receiving the Opinion on the Record of Drug Advertisement Examination, the original drug advertisement examination authority shall give its opinions to the drug advertisement examination authority of the place where the drug advertisement is to be put on record. Where no consensus is achieved between the original drug advertisement examination authority and the drug advertisement examination authority of the place where a drug advertisement is to be put on record, the case may be submitted to the State Food and Drug Administration that shall make a final judgment.

Article 15 The valid term of a drug advertisement approval number is one year. It shall become invalid upon expiration.

Article 16 The content of an approved drug advertisement is not allowed to be changed when being published. Where any change to the drug advertisement is needed, a new drug advertisement approval number shall be obtained.

Article 17 Where an advertisement applicant publishes a drug advertisement by itself, it shall keep the original Application Form for Drug Advertisement for two years for future check.

Where an advertisement publisher or advertising operator is authorized by the applicant to publish a drug advertisement, it shall check the original Application Form for Drug Advertisement, publish the advertisement in accordance with the approved content and keep a copy of the Applicant Form for Drug Advertisement for two years for future check.

Article 18 Where there is any of the following circumstances for an approved drug advertisement, the original drug advertisement examination authority shall issue a Notice of Drug Advertisement Re-examination (Appendix 3) and conduct the re-examination. The drug advertisement may continue to be published during the re-examination.

(1) The State Food and Drug Administration finds that the content of the drug advertisement approved by the drug advertisement examination authority is not in conformity with the provisions;
(2) A supervision and control authority for advertisement at or above provincial level makes a re-examination proposal;
(3) Other circumstances where a re-examination is required by a drug advertisement examination authority.

After re-examination, where the drug advertisement is not in conformity to the statutory requirements, the Application Form for Drug Advertisement shall be taken back and the original drug advertisement approval number shall become invalid.

Article 19 Drug advertisement examination authorities shall cancel the drug advertisement approval number in any of the following circumstances:
(1) Where a Drug Manufacturing Certificate or the Drug Supply Certificate is revoked;
(2) Where a drug approval document is withdrawn or cancelled;
(3) Where the State Food and Drug Administration or the drug regulatory department of the province, autonomous region or municipality directly under the Central Government instructs to stop the production, sales and use of the drug.

Article 20 For any alteration to the approved content of a drug advertisement for false propaganda, the drug regulatory departments shall instruct to stop the publication of the advertisement immediately, revoke the drug advertisement approval number, and shall not accept any application for advertisement of the drug within one year.

Article 21 Where any illegal advertisement in which the scope of indications (functions) of the drug is expanded without authorization, the therapeutic effectiveness is exaggerated extremely, or which seriously cheats or misleads the customers, is found, the drug regulatory department at or above the provincial level shall take mandatory administrative measures to suspend the sales of the drug within their administrative area and order the enterprise that illegally publishes the drug advertisement to issue a correction notice in relevant local media.

After the enterprise that illegally publishes the drug advertisement issues a correction notice as required, the drug regulatory department at or above the provincial level shall make a decision on lifting the mandatory administrative measures within 15 working days; where it is necessary to test the drug, the drug regulatory departments shall determine whether to lift the mandatory administrative measures within 15 days as from the day when the test report is issued.

Article 22 Where a drug advertisement application providing false materials is found by the drug advertisement examination authority during the examination, no further application of the enterprise in respect of the advertisement of the drug shall be accepted within one year.

Article 23 Where a drug advertisement with an approval number is found by the drug advertisement examination authority to have provided false materials, such drug advertisement approval number shall be revoked and no further application from the enterprise in respect of the advertisement of the drug shall be accepted within three years.

Article 24 Any drug advertisement, of which the approval number is taken back, cancelled or revoked in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, shall be discontinued for publication immediately; non-local drug advertisement examination authorities shall stop filing the record of the advertisement of the enterprise with the drug advertisement approval number.

Where a drug advertisement examination authority takes back, cancels or withdraws a drug advertisement approval number in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, it shall notify the supervision and control authority for advertisements at the same level within five working days from the day when the administrative decision on the matter is made; the supervision and control authority for advertisements shall handle it in accordance with law.

Article 25 Where a non-local drug advertisement is found not put on record in the drug advertisement examination authority of the place where it is published, the authority shall instruct to file its record within a time limit. If the record is not filed within the time limit, the drug advertisement in the above-mentioned place shall be suspended.

Article 26 The drug regulatory department at or above the county level shall monitor and check the publishing of drug advertisement that has been examined and approved. For any illegal drug advertisements, drug regulatory departments at all levels shall fill in the Notice on the Transfer of Illegal Drug Advertisement (Appendix 4) and transfer it to an supervision and control authority for advertisements at the same level together with such materials as samples of illegal drug advertisement; where the content of approved non-local drug advertisement is altered without permission, the drug advertisement examination authority of the place where the advertisement is published shall advise the original drug advertisement examination authority to revoke its approval number in accordance with Article 92 of the Drug Administration Law and Article 20 of the Provisions.

Article 27 Where an illegal drug advertisement is published and the circumstances are serious, the drug regulatory department of province, autonomous region or municipality directly under the Central Government shall announce the matter to the public and timely report it to the State Food and Drug Administration. The State Food and Drug Administration shall summarize and release the collected information periodically.

Where any false or illegal drug advertisement is published and the circumstances are serious, it shall be announced to the public jointly by the State Administration for Industry and Commerce and the State Food and Drug Administration if necessary.

Article 28 For any drug advertisement published without approval, or the contents published inconsistent with the approved ones, the supervision and control authority for advertisements shall impose a punishment in accordance with Article 43 of the Advertisement Law; where it constitutes false advertisement or misleading propaganda, the supervision and control authorities for advertisements shall impose a punishment in accordance with Article 37 of the Advertisement Law and Article 24 of Anti-Unfair Competitions Law.

In the process of investigation of an illegal drug advertisement, where there is a need to affirm any drug technical information, the supervision and control authority for advertisements shall notify the drug regulatory department at or above the provincial level. The drug regulatory department at or above the provincial level shall give the affirmation result to the supervision and control authorities for advertisements within ten working days after receiving the notification.

Article 29 The staff members that examine and supervise drug advertisements shall be trained in such laws and regulations as the Advertisement Law and the Drug Administration Law. Where the staff members in drug advertisement examination department or in supervision and control authority for drug advertisements neglect their duty, abuse their power, or practice favoritism and commit irregularities, they shall be given an administrative sanction in accordance with law. If a crime is constituted, they shall be investigated for their criminal liabilities in accordance with law.

Article 30 A drug advertisement approval number shall be “X Yao Guang Shen (Shi) No. 0000000000", “X Yao Guang Shen (Sheng) No. 0000000000", “X Yao Guang Shen (Wen) No. 0000000000". “X” is the abbreviation for a province, autonomous region or municipality directly under the Central Government. “0000000000” is a number with ten digits, in which the first six represent year and month of the examination, and the last four represent advertisement approval sequence number. “Shi”, “Sheng” or “Wen” represents certain classification code used in advertising media.

Article 31 These Provisions shall come into force as of May 1, 2007. The Provisions for Drug Advertisement Examination issued by the State Administration for Industry and Commerce and the Ministry of Health (Decree of State Administration for Industry and Commerce No. 25) on March 22, 1995 shall be annulled therefrom.